The Ipamorelin + CJC-1295 Stack Explained
Why these two peptides are better together. Understanding GHRP/GHRH synergy for optimal GH release.
Introduction
If you've ever gone down a research-peptide rabbit hole for growth hormone, you've seen this pairing: Ipamorelin + CJC-1295. It's the most-cited GH-secretagogue stack in the peptide world, widely used (off-label) for sleep, recovery, and body composition. Here's why they work together — and what the research actually supports.
Summary: Ipamorelin is a ghrelin-receptor agonist that triggers a discrete GH pulse. CJC-1295 is a GHRH analog that extends the amplitude and duration of that pulse. Together, they produce sustained, physiological GH elevation without the side effects of direct GH administration. Research backing is moderate; human trial data is limited.
Quick background on growth hormone
Your pituitary gland releases GH in pulses, mostly at night during deep sleep. Two upstream hormones control this:
- GHRH (Growth Hormone Releasing Hormone) — released from the hypothalamus. Tells the pituitary to release GH. Think of it as the gas pedal.
- Ghrelin — released from the stomach, especially when empty. Binds the GHS-R1a receptor on pituitary cells, amplifying GH release. Think of it as the turbocharger.
When GHRH and ghrelin fire together, GH output is synergistically higher than either alone. This is the pharmacological insight behind the stack.
Ipamorelin — the ghrelin-mimetic
Ipamorelin is a synthetic pentapeptide (5 amino acids) designed to bind the ghrelin receptor (GHS-R1a) and trigger GH release. Its key feature: selectivity. Unlike older GHRPs (GHRP-2, GHRP-6), ipamorelin doesn't meaningfully raise:
- Cortisol (the stress hormone)
- Prolactin (associated with side effects like lactation)
- ACTH (which drives cortisol)
This is what makes it popular. You get the GH pulse without the nastier endocrine side effects.
Half-life: ~2 hours. Short enough that it produces a discrete pulse rather than sustained elevation. That's actually the goal for GH — your body evolved with pulsatile signaling.
CJC-1295 — the GHRH extender
CJC-1295 is a modified GHRH analog. It comes in two forms:
- CJC-1295 no-DAC (also called Mod GRF 1-29 or Sermorelin analog) — a GHRH(1-29) peptide with amino acid substitutions that resist degradation. Half-life ~30 minutes.
- CJC-1295 with DAC (Drug Affinity Complex) — same molecule plus a linker that binds albumin. Half-life ~7–8 days.
Which form is used in the stack? Almost always no-DAC. The goal is to pulse GH, not saturate GHRH receptors continuously. Continuous elevation (from DAC) can cause receptor downregulation and defeats the point.
Why they stack
When GHRH (CJC-1295 no-DAC) and a ghrelin agonist (Ipamorelin) fire together:
- GHRH tells somatotrophs "release GH now."
- Ipamorelin simultaneously amplifies that signal via GHS-R1a.
- The resulting GH pulse is 2–5x higher amplitude than either alone.
- Because both peptides clear quickly, the pulse resolves naturally — no sustained elevation, no receptor desensitization.
This mimics the body's natural GH secretory rhythm more closely than direct GH injection. Your pituitary is still doing the work; you're just telling it to.
Typical protocols
Standard "GH pulse" protocol (reported research range):
- Ipamorelin: 100–300 mcg subcutaneous
- CJC-1295 (no-DAC): 100 mcg subcutaneous
- Combined: Drawn in the same syringe, injected together
- Frequency: 1–3x daily
- Timing:
- Morning (fasted) — highest natural GH response
- Pre-workout — supports training recovery
- Pre-bed, 2+ hours post-food — enhances natural sleep GH pulse
Cycle length: 8–16 weeks, often cycled to avoid receptor adaptation.
Empty stomach is critical for both. Ghrelin signaling is suppressed by food intake, and blood glucose blunts GH release. If you inject within 30 minutes of eating, expect half the effect.
What the research supports
- Direct GH/IGF-1 elevation — well established. Multiple trials show CJC-1295 + GHRP combinations produce 2–5x GH AUC versus placebo.
- Sleep quality improvements — reported anecdotally and in small studies, consistent with natural GH's role in deep sleep.
- Body composition changes — modest. A 2006 CJC-1295 trial showed increased IGF-1 and modest fat loss over 28 days.
- Recovery from training — anecdotal but plausible given IGF-1's role in tissue repair.
What the research does NOT strongly support:
- Anti-aging / longevity — very thin evidence. GH elevation in older adults has been associated with mixed outcomes.
- Dramatic muscle gain — the stack produces physiological (not supraphysiological) GH levels. Don't expect anabolic-steroid-level changes.
- Fat loss at specific areas — spot fat loss via peptides is not supported.
Side effects
Reported side effects:
- Injection site reactions (mild, common)
- Headache (especially with first few doses)
- Tingling/numbness in extremities (transient, caused by rapid IGF-1 rise)
- Mild water retention
- Fatigue or lethargy at higher doses
- Hunger increase from ipamorelin (ghrelin-mediated — it's in the name "growth hormone-releasing peptide")
Serious concerns (rare but possible):
- Hyperglycemia — GH elevation opposes insulin action
- Joint pain at high IGF-1 levels
- Theoretical cancer concern in undiagnosed malignancy (GH/IGF-1 are proliferative)
Do not use if: You have active cancer or cancer history, uncontrolled diabetes, severe obesity with hypothalamic dysfunction, or are pregnant/nursing.
Alternatives and comparisons
| Compound | Role | Strength | Side-effect profile |
|---|---|---|---|
| Ipamorelin + CJC-1295 | GHRP + GHRH | Moderate pulse, clean | Minimal |
| Sermorelin | GHRH alone | Modest | Clean |
| Tesamorelin | Stabilized GHRH | Strong, FDA-approved | Clean (injection site) |
| GHRP-2/GHRP-6 | Older GHRPs | Strong pulse | Cortisol, prolactin, hunger |
| MK-677 (ibutamoren) | Oral ghrelin agonist | Sustained, not pulsatile | Water retention, insulin resistance |
For many researchers, tesamorelin alone now makes more sense than the Ipa+CJC stack — it's FDA-approved, has real human efficacy data, and produces clean GH elevation without mixing compounds.
What's new in 2026
- GHRH class is shifting to tesamorelin for serious research protocols. CJC-1295's regulatory status in 2026 is more restricted than it was five years ago.
- Ghrelin-signaling research has become more nuanced — we now understand ghrelin receptor activation has non-GH effects on appetite, reward, and mitochondrial function.
- MK-677 (oral alternative) is increasingly compared to injected Ipa+CJC for convenience, though with worse metabolic profile.
Read next: The Ipamorelin profile for structured data, or compare tesamorelin — the FDA-approved option researchers are migrating toward.
PEPGAINS RESEARCH
Independent peptide research, read by 8,400 researchers. Every claim cited, every affiliate disclosed.